Deal Details
Initial Public Offering
Summary
Baird served as a co-manager in this offering
About
Complete Genomics, Inc. (NASDAQ:GNOM) (“Complete Genomics” or the “Company”) recently announced the pricing of its initial public offering of 6,000,000 shares of common stock at $9.00 per share, generating gross proceeds of $54.0 million for the Company. The Company intends to use the net proceeds from the offering for capital expenditures to expand the sequencing and computing capacity in its Mountain View and Santa Clara leased facilities, to finance the further development of its sequencing technology and services, for sales and marketing activities, and for working capital and other general corporate purposes. Complete Genomics offered all of the 6,000,000 shares of common stock and has granted the underwriters an option to purchase an additional 900,000 shares to cover over-allotments. Complete Genomics is a life sciences company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics’ proprietary human genome sequencing technology with its advanced informatics and data management software and its innovative, end-to-end, outsourced service model to provide customers with data that is immediately ready to be used for genome-based research.For additional information about this transaction, please contact:
- Date
- November 2010
- Company
- Complete Genomics, Inc.
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
